分子靶向药物吉非替尼治疗晚期非小细胞肺癌的疗效观察  

Observation on the Curative Effect of Molecular Targeted Drug Gefitinib in the Treatment of Advanced Non-Small Cell Lung Cancer

作　　者：陈荣辉[1] 彭玉龙[1] 曹永新[1] 邓惠君[1] 张露 黄连涛[1] 

机构地区：[1]广东省东莞东华医院肿瘤内科,广东东莞523110

出　　处：《临床医学工程》2018年第1期59-60,共2页Clinical Medicine & Engineering

摘　　要：目的观察分子靶向药物吉非替尼治疗晚期非小细胞肺癌的临床效果。方法选取我院2015年6月至2017年6月收治的40例晚期非小细胞肺癌患者,随机分为研究组和对照组各20例。对照组采用传统常规化疗方案治疗,研究组应用分子靶向药物吉非替尼治疗。对比分析两组患者的疾病控制率和不良反应发生率。结果研究组的疾病控制率为95%,明显高于对照组的70%,差异有统计学意义(P<0.05)。研究组的不良反应发生率为10%,明显低于对照组的40%,差异有统计学意义(P<0.05)。结论分子靶向药物吉非替尼治疗晚期非小细胞肺癌的效果较好,能够有效控制病情发展,不良反应发生率较低,安全性较高,值得临床推广。Objective To observe the clinical effect of molecular targeted drug gefitinib in the treatment of advanced non-small cell lung cancer. Methods 40 cases of patients with advanced non-small cell cancer admitted to our hospital from June 2015 to June 2017 were selected and randomly divided into study group and control group, with 20 cases in each group. The control group was treated with conventional chemotherapy regimen, while the study group was treated with molecular targeted drug gefitinib. The disease control rate and incidence of adverse reactions were analyzed and compared between two groups. Results The disease control rate of the study group was 95%, significantly higher than 70% of the control group, with statistical difference （P〈0.05）. The incidence of adverse reactions of the study group was 10%, significantly lower than 40% of the control group, with statistical difference （P 〈0.05）. Conclusions Molecular targeted drug gefitinib in the treatment of advanced non-small cell lung cancer has better effect, can effectively control the disease progression, and has lower incidence of adverse reactions and higher safety, which is worthy of clinical promotion.

关 键 词：晚期非小细胞肺癌 分子靶向药物 常规化疗 吉非替尼 

分 类 号：R734.2[医药卫生—肿瘤]